Nothing Special   »   [go: up one dir, main page]

DE3908749A1 - Herz- und kreislaufmedikament - Google Patents

Herz- und kreislaufmedikament

Info

Publication number
DE3908749A1
DE3908749A1 DE19893908749 DE3908749A DE3908749A1 DE 3908749 A1 DE3908749 A1 DE 3908749A1 DE 19893908749 DE19893908749 DE 19893908749 DE 3908749 A DE3908749 A DE 3908749A DE 3908749 A1 DE3908749 A1 DE 3908749A1
Authority
DE
Germany
Prior art keywords
osmium
water
cardiovascular medicine
liquid
hesperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19893908749
Other languages
English (en)
Inventor
Lothar Goertz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19893908749 priority Critical patent/DE3908749A1/de
Publication of DE3908749A1 publication Critical patent/DE3908749A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06Benzopyran radicals
    • C07H17/065Benzo[b]pyrans
    • C07H17/07Benzo[b]pyran-4-ones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

Herstellung und Zusammensetzung
Hesperidin flüssig 6 ml, Osmium flüssig 21/2 ml - sollen zusammen 5 Minuten bei mittlerer Umdrehungs­ zahl zentrifugiert werden. Dann kann man das Präparat nach 10 Mi­ nuten in Gebrauch nehmen.
Dieses Präparat kann angewendet werden bei immunologischen, virologischen und bakteriologischen Entzündungen der Herz­ kranzgefäße.
Wechselwirkungen sind i. M. nicht bekannt.

Claims (6)

    OberbegriffKennzeichnender Teil
  1. Hercolith - Handelsname und Waren­ bezeichnung
  2. Hesperidin 3 ml, verflüssigt in 3 ml destilliertem Wasser
  3. Osmium (Osmium-Säure - löslich in Wasser 7,24 Gramm bei 100 ml Wasser, bei +25 Grad Celsius) 1/2 ml Osmium (Osmium-Säure - löslich in Wasser, 7,24 Gramm bei 100 ml Wasser, bei +25 Grad Celsius) - verflüssigt in 2 ml destilliertem Wasser
  4. Hesperidin flüssig 6 ml
  5. Osmium flüssig 21/2 ml
  6. Gekennzeichnet durch Osmium
DE19893908749 1989-03-17 1989-03-17 Herz- und kreislaufmedikament Withdrawn DE3908749A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19893908749 DE3908749A1 (de) 1989-03-17 1989-03-17 Herz- und kreislaufmedikament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19893908749 DE3908749A1 (de) 1989-03-17 1989-03-17 Herz- und kreislaufmedikament

Publications (1)

Publication Number Publication Date
DE3908749A1 true DE3908749A1 (de) 1990-09-20

Family

ID=6376552

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19893908749 Withdrawn DE3908749A1 (de) 1989-03-17 1989-03-17 Herz- und kreislaufmedikament

Country Status (1)

Country Link
DE (1) DE3908749A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543555A1 (de) * 1991-11-18 1993-05-26 Merrell Dow Pharmaceuticals Inc. Phosphorylierte Flavonoide zur Behandlung von Viruserkrankungen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543555A1 (de) * 1991-11-18 1993-05-26 Merrell Dow Pharmaceuticals Inc. Phosphorylierte Flavonoide zur Behandlung von Viruserkrankungen
WO1993009786A1 (en) * 1991-11-18 1993-05-27 Merrell Dow Pharmaceuticals Inc. Phosphorylated flavanoids in the treatment of viral diseases

Similar Documents

Publication Publication Date Title
ATE69169T1 (de) Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung.
JPS57159718A (en) Novel protein and obtaining process
Hellberg et al. Studies on the coronary microcirculation by direct visualization
DE3908749A1 (de) Herz- und kreislaufmedikament
DE3879919D1 (de) Verfahren zur herstellung von hexitolanhydriden, hexondactonen, hexosen und hexosiden.
Pawan et al. Distribution of alcohol in urine and sweat after drinking
Bacchus Serum seromucoid and acid mucopolysaccharide in the Marfan syndrome
BE789679A (fr) Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation
Landis Factors controlling the movement of fluid through the human capillary wall
ES2068527T3 (es) Compuesto polisacaridico deslipidado, procedimiento de preparacion, composiciones que lo comprenden.
SU1270706A1 (ru) Способ определени фосфолипидов в инфарктной зоне сердечной мышцы
WEST et al. Effects of aortic insufficiency on circulatory dynamics of the dog: With special reference to coronary blood flow and cardiac oxygen consumption
Rosenblum Erythrocyte velocity and fluorescein transit time in the cerebral microcirculation of macroglobulinemic mice: differential effect of a hyperviscosity syndrome on the passage of erythrocytes and plasma
EP0206551A3 (de) 6-Jodiumethylierte Stärke und Verfahren zu deren Herstellung
BISHOP et al. External rupture of the heart causing a systolic murmur and thrill
Braun et al. Central blood volume, cardiac output, and pulmonary vascular pattern in mitral stenosis
Gauthier-Rahman et al. Leukocyte migration inhibition in propranolol-induced pneumonitis: evidence for an immunologic cell-mediated mechanism
KR890002342A (ko) 안트라퀴논계색소 및 이색소를 사용한 편광필름
Donnelly Congestive Heart Failure and Anemia: Report From Veterans Administration Hospital, Hines, Illinois
Ugarte et al. Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine
Orlova et al. CONTENT OF SIALIC ACIDS IN TISSUES IN NORM AND AT EARLY STAGES OF MYOCARDIAL INFARCTION
이강호 Chemical Modification of Fish Protein
Jokl et al. Sudden cardiac death of pilots in flight. With special consideration of syncope due to silent ischemic heart disease and the differential diagnosis of other causes of episodes of incapacitation, unconsciousness, confusion and amnesia in flying personnel
BURCHELL et al. Cardiac Isomers—A Pedagogic Exercise in the June Supplement
Hada et al. Diffuse hypoplasia of the aorta as a possible cause of cardiac hypertrophy

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8139 Disposal/non-payment of the annual fee